Niccolò Siliquini
13PUBLICATIONS
13CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Feb 19, 2024
Safety of dupilumab in patients with cancer.Nicole Macagno, Luca Mastorino, Niccolò Siliquini
|Apr 28, 2023
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.L Mastorino, S Susca, C Cariti
|Apr 28, 2023
Exacerbation of acquired perforating dermatosis following SARS-CoV-2 vaccination.Nadia Sciamarrelli, Niccolò Siliquini, Luca Mastorino
|Jul 07, 2022
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo
|Jun 28, 2022
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.Luca Mastorino, Niccolò Siliquini, Gianluca Avallone
|Feb 14, 2022
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.Luca Mastorino, Sara Susca, Matteo Megna
Pageof 3
Frequent Collaborators
13 joint publications
Simone Ribero
8 joint publications
Luca Mastorino
7 joint publications
Pietro Quaglino
4 joint publications
Maria Teresa Giura
1 joint publications
A Ramondetta
1 joint publications
C Cariti
1 joint publications
Gabriele Roccuzzo
1 joint publications
Gianluca Avallone
1 joint publications
Gabriella Fabbrocini
1 joint publications
Marco Rubatto
